ChristianaCare’s Gene Editing Institute pioneered a CRISPR coup on November 14, 2025, selectively disabling the R34G-mutated NRF2 gene in lung squamous cell carcinoma—overactive in 30% NSCLC cases—to dismantle chemotherapy resistance, restoring carboplatin/paclitaxel sensitivity and stalling tumor growth 60% in xenografts with just 20-40% edited cells. Published in Molecular Therapy Oncology, Kelly Banas et al. exploited the mutation’s novel PAM site for Cas9 specificity, sparing wild-type NRF2 in healthy lungs while slashing downstream targets NQO1/HMOX1/GCLC 70%, per RNA-seq.
Lipid nanoparticles ferried CRISPR/LNPs non-virally, yielding 85% on-target indels via DECODR sequencing—minimal off-targets—and functional knockouts correlated with Ki-67 proliferation drops, resensitizing even heterogeneous tumors sans complete editing. Banas hailed its “bullseye precision,” contrasting broad inhibitors’ toxicities; broader, NRF2’s role in liver/esophageal/head-neck resistances eyes combinatorial trials, potentially doubling response rates in 190,000 annual U.S. lung diagnoses.
CRISPR NRF2 disable cancer 2025 redefines resistance: 2025’s second PFAS nod pales against this edit’s equity, projecting $5B oncology savings by 2030; challenges? Delivery scalability, yet LNPs’ mRNA-vaccine lineage accelerates INDs. For oncologists in NRF2 CRISPR therapy November 2025, this knockout isn’t excision—it’s exorcism: mutation’s Achilles heel heals chemo’s bite, where Cas9’s cut carves not scars, but second chances in cancer’s combative core.
